{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6"}]}],"title":"Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}]}],"title":"Year 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3"}]}],"title":"Year 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"}],"units":"Participants"}],"description":"Grading of Chronic GVHD:\n\nLimited: Localized skin involvement and/or hepatic dysfunction due to chronic GVHD\n\nExtensive:\n\nOne or more of the following:\n\nGeneralized skin involvement Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis Involvement of the eye: Schirmer's test with \\<5 mm wetting Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy Involvement of any other target organ\n\nChronic GVHD Severity:\n\nMild: Signs and symptoms of cGVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy.\n\nModerate: Signs and symptoms of cGVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy.\n\nSevere: Signs and symptoms of cGVHD limit function substantially despite appropriate therapy or are progressive through second line systemic therapy","groups":[{"description":"Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0\n\nTherapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.\n\nBusulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.\n\nIV Busulfan is available and diluted and administered per package insert guidelines.\n\nCyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including","id":"OG000","title":"Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)"}],"paramType":"NUMBER","populationDescription":"This is a cumulative incidence of cGVHD at 1 year, 2 years, and 3 years. A total of 99 patients (out of 147) developed cGVHD, 86 patients (87%) with extensive stage cGVHD and 13 patients (13%) with limited stage cGVHD.","reportingStatus":"POSTED","timeFrame":"Years 1, 2 and 3","title":"Chronic Graft-Versus-Host Disease (cGVHD) Outcome","type":"SECONDARY","unitOfMeasure":"percentage of analyzed participants"}